Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.

Abstract

AIM Meta-analyses and large cohort studies provide confusing results on the association of the CYP3A5 6986A>G allelic variant and adverse outcomes in kidney transplant recipients under tacrolimus-based immunosuppressive regimen. A residual effect of CYP3A5 recipient genotype is unexpected if kidney transplant recipients have similar exposure of tacrolimus. PATIENTS & METHODS We have undertaken a population-based, observational study, to investigate all the consecutive patients who received a kidney transplant at the Necker hospital between 2005 and 2015, who were treated with tacrolimus and for whom the CYP3A5 genotype was available. RESULTS & CONCLUSION We analyzed 577 patients followed for up to 5 years. We found a significant association of CYP3A5 genotypes with tacrolimus daily dose as well as with tacrolimus dose-adjusted concentrations. We however found no association of CYP3A5 genotypes with histology scores on biopsies, measured renal function, biopsy-proven acute rejection episodes and graft survival.

DOI: 10.2217/pgs-2016-0146

Statistics

0500100015002017
Citations per Year

141 Citations

Semantic Scholar estimates that this publication has 141 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Flahault2017ClinicalIO, title={Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.}, author={Adrien Flahault and Dany Anglicheau and Marie-Anne Loriot and Eric Thervet and Nicolas Pallet}, journal={Pharmacogenomics}, year={2017}, volume={18 2}, pages={165-173} }